Summary

China Alzheimer’s Disease Diagnostics Market Summary

The China Alzheimer’s disease diagnostics market was estimated at USD 319.6 million in 2024 and is projected to reach USD 617.8 million by 2030, growing at a CAGR of 11.7% from 2025 to 2030. The increasing prevalence of Alzheimer’s disease (AD), growing adoption of personalized products, growing use of biomarkers in disease diagnostics, and growing technological advancements in medical imaging are expected to drive the market growth.

Increasing government investments and R&D studies are further propelling growth. One major growth driver for China’s Alzheimer’s disease diagnostics market is its rapidly aging population. With over 280 million people aged 60 and above, the country faces a surge in age-related diseases, including Alzheimer’s. This demographic shift is increasing demand for early detection and intervention tools. In response, the Chinese government is prioritizing dementia screening under its national health agenda. Public hospitals are expanding diagnostic infrastructure, and local biotech firms are accelerating R&D in biomarker testing. Additionally, collaborations with global firms are boosting access to advanced imaging and blood-based diagnostics. This environment fosters strong market expansion for Alzheimer’s diagnostics in China.

In June 2024, the launch of LEQEMBI in China by Eisai Co., Ltd. and Biogen Inc. marked a significant driving factor in the market. Following its approval in January 2024 for treating mild cognitive impairment (MCI) and mild Alzheimer's dementia, China became the third country to introduce LEQEMBI, after the U.S. and Japan. With an estimated 17 million individuals in China affected by early-stage Alzheimer's in 2024, the number is expected to grow with the aging population. Eisai is actively building an early AD diagnosis and treatment pathway. This approach combines online and offline services, including collaboration with commercial health insurance companies, private health checkups, and nursing homes.

In addition, Eisai fosters early detection through disease awareness campaigns, pre-screening opportunities, and referrals to specialized hospitals or "Yin Fa Tong," an online platform developed with JD Health. Eisai’s efforts, including using blood biomarkers for definitive diagnosis, are poised to significantly impact the market growth and development, supporting early detection and treatment within a comprehensive dementia care ecosystem.

China's aging population has expanded rapidly since the 2010 census, leading to a significant rise in the incidence, morbidity, and mortality of age-related diseases, particularly Alzheimer's disease (AD). The increasing prevalence of AD poses substantial medical and social challenges, severely impacting both urban and rural communities. Recent data reveal that 15.07 million people aged 60 and over in China suffer from dementia, with 9.83 million affected by AD, 3.92 million by vascular dementia, and 1.32 million by other forms of dementia.

Furthermore, 15.5% of those over 60 have mild cognitive impairment (MCI), affecting approximately 38.77 million individuals. The economic burden is immense, with AD treatment costs soaring from USD 167.74 billion in 2015 to a projected USD 1.8 trillion by 2050. Despite this, China's diagnosis and treatment rates for AD remain alarmingly low, compounded by a shortage of medical specialists and limited public awareness. Addressing these issues through government-led initiatives to enhance AD prevention and treatment is urgently needed to mitigate the growing crisis.

Initiatives like the 'Guangci Home Ruijian Cognitive Science Popularization Volunteer Service Team' at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, represent key driving factors in the market. This team conducts disease screening and educational outreach in communities and homes, emphasizing 'Early prevention, detection, diagnosis, and treatment.' Supported by the Shanghai Voluntary Service Public Welfare Foundation, such efforts highlight the growing focus on early intervention.

Similarly, the Beijing Senior Care Centre’s decade-long program uses art therapy to meet the deeper needs of seniors with dementia, enhancing their well-being. In addition, the Shanghai Jian’ai Charity Development Center’s ‘Anti-dementia Manual Assemblage’ activities foster social interaction among older adults through creative exercises. The Shanghai Brain Health Alliance, established by 141 institutions under the guidance of the Shanghai Medical Society General Medical Section and in line with WHO's Global Action Plan on Dementia, aims to enhance the diagnosis and treatment of cognitive impairment. By integrating prevention, screening, diagnosis, treatment, and long-term management into a cohesive system, these initiatives are set to significantly boost the detection and treatment rates of Alzheimer's disease, thereby driving advancements in the market in China.

Currently, there are no standardized cutoff values for Alzheimer's disease (AD) biomarkers in the Chinese population, which presents a challenge for consistent diagnosis. However, as part of the Alzheimer’s Association Quality Control (QC) program for cerebrospinal fluid (CSF) biomarkers, researchers have made significant progress by establishing diagnostic cutoff values for core CSF biomarkers in a Chinese cohort. Using methods recommended by the QC program, they developed an optimal diagnostic model that combines these biomarkers. This study represents a critical step toward defining uniform cutoff values tailored to the Chinese population, facilitating the integration of CSF biomarkers into clinical practice. This advancement is poised to enhance the accuracy and reliability of AD diagnostics in China, thereby driving growth in the country's Alzheimer’s disease diagnostics market.

China Alzheimer's Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the China Alzheimer’s disease diagnostics market report on the basis of diagnostic technique, type and end-use:

• Diagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030)
• Biomarkers
o CSF Biomarkers
o Blood-based Biomarkers
• Imaging Techniques
• Genetic Testing
• Cognitive Assessment Tests
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Triage
• Diagnosis
• Screening
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Diagnostic Laboratories
• Academic and Research Institutes

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Procedure
1.2.2. End Use
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Procedure outlook
2.2.2. End Use outlook
2.3. Competitive Insights
Chapter 3. China Alzheimer’s Disease Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. China Alzheimer’s Disease Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. China Alzheimer’s Disease Diagnostics Market: Pipeline Analysis
Chapter 4. China Alzheimer’s Disease Diagnostics Market: Diagnostic Technique Estimates & Trend Analysis
4.1. Diagnostic Technique Segment Dashboard
4.2. China Alzheimer’s Disease Diagnostics Market: Diagnostic Technique Movement Analysis
4.3. China Alzheimer’s Disease Diagnostics Market Size & Trend Analysis, by Diagnostic Technique, 2018 to 2030 (USD Million)
4.4. Biomarkers
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Imaging Techniques
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.6. Genetic Testing
4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.7. Cognitive Assessment Tests
4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. China Alzheimer’s Disease Diagnostics Market: Type Estimates & Trend Analysis
5.1. Type Segment Dashboard
5.2. China Alzheimer’s Disease Diagnostics Market: Type Movement Analysis
5.3. China Alzheimer’s Disease Diagnostics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Triage
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Diagnosis
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Screening
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. China Alzheimer’s Disease Diagnostics Market: End Use Estimates & Trend Analysis
6.1. End Use Segment Dashboard
6.2. China Alzheimer’s Disease Diagnostics Market: End User Movement Analysis
6.3. China Alzheimer’s Disease Diagnostics Market Size & Trend Analysis, by End User, 2018 to 2030 (USD Million)
6.4. Hospitals
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Diagnostic Laboratories
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Academic and Research Institutes
6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
1.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. FujireBio
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. ALZpath
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Quanterix
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Hoffmann-La Roche
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Life Molecular Imaging
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Quest Diagnostics
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Labcorp
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives